SG11201811151PA - Extracellular vesicle comprising a fusion protein having fc binding capacity - Google Patents
Extracellular vesicle comprising a fusion protein having fc binding capacityInfo
- Publication number
- SG11201811151PA SG11201811151PA SG11201811151PA SG11201811151PA SG11201811151PA SG 11201811151P A SG11201811151P A SG 11201811151PA SG 11201811151P A SG11201811151P A SG 11201811151PA SG 11201811151P A SG11201811151P A SG 11201811151PA SG 11201811151P A SG11201811151P A SG 11201811151PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- evs
- pct
- extracellular vesicle
- fusion protein
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 2
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000011248 coating agent Substances 0.000 abstract 2
- 238000000576 coating method Methods 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 241000501754 Astronotus ocellatus Species 0.000 abstract 1
- 239000000232 Lipid Bilayer Substances 0.000 abstract 1
- LUTSRLYCMSCGCS-BWOMAWGNSA-N [(3s,8r,9s,10r,13s)-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,16-decahydrocyclopenta[a]phenanthren-3-yl] acetate Chemical compound C([C@@H]12)C[C@]3(C)C(=O)CC=C3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)C)C1 LUTSRLYCMSCGCS-BWOMAWGNSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1612643.5A GB2552473A (en) | 2016-07-21 | 2016-07-21 | Surface decoration of extracellular vesicles |
| PCT/EP2017/068476 WO2018015535A1 (fr) | 2016-07-21 | 2017-07-21 | Vésicule extracellulaire comprenant une protéine de fusion ayant une capacité de liaison de fc |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811151PA true SG11201811151PA (en) | 2019-01-30 |
Family
ID=56894359
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811151PA SG11201811151PA (en) | 2016-07-21 | 2017-07-21 | Extracellular vesicle comprising a fusion protein having fc binding capacity |
| SG10202100597TA SG10202100597TA (en) | 2016-07-21 | 2017-07-21 | Extracellular Vesicle Comprising a Fusion Protein Having FC Binding Capacity |
| SG10202100598RA SG10202100598RA (en) | 2016-07-21 | 2017-07-21 | Uses of Extracellular Vesicle Comprising a Fusion Protein Having FC Binding Capacity |
| SG11201811152YA SG11201811152YA (en) | 2016-07-21 | 2017-07-21 | Uses of extracellular vesicle comprising a fusion protein having fc binding capacity |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202100597TA SG10202100597TA (en) | 2016-07-21 | 2017-07-21 | Extracellular Vesicle Comprising a Fusion Protein Having FC Binding Capacity |
| SG10202100598RA SG10202100598RA (en) | 2016-07-21 | 2017-07-21 | Uses of Extracellular Vesicle Comprising a Fusion Protein Having FC Binding Capacity |
| SG11201811152YA SG11201811152YA (en) | 2016-07-21 | 2017-07-21 | Uses of extracellular vesicle comprising a fusion protein having fc binding capacity |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20230181757A1 (fr) |
| EP (3) | EP3487529A1 (fr) |
| JP (4) | JP7254016B2 (fr) |
| KR (2) | KR20190032479A (fr) |
| CN (2) | CN109689098A (fr) |
| AU (2) | AU2017299214A1 (fr) |
| BR (2) | BR112019001108A2 (fr) |
| CA (2) | CA3031186A1 (fr) |
| GB (1) | GB2552473A (fr) |
| MX (2) | MX2019000863A (fr) |
| SG (4) | SG11201811151PA (fr) |
| WO (2) | WO2018015535A1 (fr) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130280334A1 (en) | 2010-09-24 | 2013-10-24 | Massachusetts Institute Of Technology | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents |
| GB2552774A (en) * | 2016-07-12 | 2018-02-14 | Evox Therapeutics Ltd | EV-Mediated delivery of binding protein-small molecule conjugates |
| GB2552473A (en) * | 2016-07-21 | 2018-01-31 | Evox Therapeutics Ltd | Surface decoration of extracellular vesicles |
| WO2018144991A1 (fr) | 2017-02-03 | 2018-08-09 | The Brigham And Women's Hospital, Inc. | Gels auto-assemblés formés avec des médicaments anti-rétroviraux, leurs promédicaments et leurs utilisations pharmaceutiques |
| GB201702863D0 (en) * | 2017-02-22 | 2017-04-05 | Evox Therapeutics Ltd | Improved loading of EVs with therapeutic proteins |
| JP2020530454A (ja) | 2017-08-07 | 2020-10-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 安全な細胞治療薬を生成するためのプラットフォーム |
| GB201717446D0 (en) * | 2017-10-24 | 2017-12-06 | Evox Therapeutics Ltd | Affinity purification of engineering extracellular vesicles |
| GB201804291D0 (en) * | 2018-03-16 | 2018-05-02 | Evox Therapeutics Ltd | Cell-mediated exosome delivery |
| CA3096745A1 (fr) | 2018-04-04 | 2019-10-10 | Alivio Therapeutics, Inc. | Gels auto-assembles pour l'administration controlee de produits biologiques et leurs procedes de fabrication |
| US11266603B2 (en) * | 2018-06-28 | 2022-03-08 | Academia Sinica | Synthetic polypeptides and uses thereof |
| KR20210032493A (ko) | 2018-07-20 | 2021-03-24 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 백혈병 억제 인자 활성을 억제하기 위한 가용성 폴리펩타이드 및 이의 사용 방법 |
| CA3108135A1 (fr) * | 2018-08-14 | 2020-02-20 | Evercyte Gmbh | Vesicules extracellulaires specifiques a une cible |
| CN108998402B (zh) * | 2018-08-28 | 2020-05-29 | 江南大学 | 一种重组枯草芽孢杆菌及其构建方法与应用 |
| EP3847650A1 (fr) | 2018-09-06 | 2021-07-14 | The Broad Institute, Inc. | Ensembles d'acides nucléiques destinés à être utilisés dans une administration ciblée |
| US20210332106A1 (en) * | 2018-10-19 | 2021-10-28 | Ohio State Innovation Foundation | Nanocarriers for lung inflammation therapy |
| KR20210081362A (ko) * | 2018-10-19 | 2021-07-01 | 오하이오 스테이트 이노베이션 파운데이션 | 골수 유래 억제 세포에 대한 표적화 치료를 위한 세포 외 소포체 |
| AU2019378108A1 (en) * | 2018-11-16 | 2021-05-27 | Evox Therapeutics Ltd | Extracellular vesicles for replacement of urea cycle proteins and nucleic acids |
| SG11202107007VA (en) * | 2018-12-27 | 2021-07-29 | Akeso Biopharma Inc | Antibody against human il-4ra and use thereof |
| US20220249373A1 (en) * | 2019-02-04 | 2022-08-11 | Codiak Biosciences, Inc. | Membrane protein scaffolds for exosome engineering |
| AU2020267758B2 (en) * | 2019-05-06 | 2023-11-23 | Thomas MALCOLM | Tailored hypoimmune nanovesicular delivery systems for cancer tumors |
| CN114258398A (zh) * | 2019-06-13 | 2022-03-29 | 总医院公司 | 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法 |
| WO2020249757A1 (fr) * | 2019-06-14 | 2020-12-17 | Philogen S.P.A | Immunoconjugués comprenant un dianticorps à chaîne unique et de l'interleukine-15 ou l'interleukine-15 et un domaine sushi du récepteur alpha de l'interleukine-15 |
| WO2020257710A1 (fr) * | 2019-06-21 | 2020-12-24 | Entelexo Biotherapeutics Inc. | Plateformes, compositions et méthodes d'administration de composés thérapeutiques |
| EP4009989A4 (fr) * | 2019-08-06 | 2023-08-23 | Ohio State Innovation Foundation | Vésicules extracellulaires thérapeutiques |
| EP3973969A4 (fr) * | 2019-09-02 | 2023-07-12 | Kyungpook National University Industry-Academic Cooperation Foundation | Composition pour la prévention ou le traitement du cancer, contenant, en tant que principe actif, des vésicules extracellulaires exprimant l'il-2 en surface |
| CN112941028A (zh) * | 2019-12-09 | 2021-06-11 | 上海细胞治疗集团有限公司 | 纳米抗体基因修饰的间充质干细胞及其制备方法与应用 |
| AU2021215935A1 (en) | 2020-02-05 | 2022-08-25 | Diadem Biotherapeutics Inc. | Artificial synapses |
| US20230149319A1 (en) * | 2020-04-13 | 2023-05-18 | City Of Hope | Cell-receptor targeted exosomes |
| CN111544453B (zh) * | 2020-04-27 | 2021-01-22 | 高连如 | 一种包含三种血管再生属性的混合干细胞注射液及其制备方法 |
| CN111560352B (zh) * | 2020-06-02 | 2023-03-24 | 新疆农业大学 | 一种病毒样囊泡及其制备方法和应用 |
| CN111905105B (zh) * | 2020-07-02 | 2023-05-05 | 华南师范大学 | 一种用于癌症靶向治疗的蛋白类纳米药物及其制备方法 |
| CN112111513A (zh) * | 2020-07-17 | 2020-12-22 | 深圳市第二人民医院 | 基于外泌体平台的新冠病毒疫苗制备方法 |
| CN113967254B (zh) * | 2020-08-04 | 2022-08-12 | 华南理工大学 | 用于多特异性抗体递送的细胞膜包覆型纳米适配子及应用 |
| CA3190722A1 (fr) * | 2020-08-05 | 2022-02-10 | Ohio State Innovation Foundation | Polypeptides adaptateurs et methodes d'utilisation de ces derniers |
| CN112285195B (zh) * | 2020-10-27 | 2021-08-10 | 江南大学 | 一种牛奶外泌体的特征性糖蛋白标志物和牛奶外泌体的特征性标志物分离方法 |
| WO2022149779A1 (fr) * | 2021-01-11 | 2022-07-14 | 주식회사 엑소코바이오 | Exosome comprenant un récepteur fc surexprimé ou une partie de celui-ci et son procédé de préparation |
| KR102252325B1 (ko) * | 2021-01-14 | 2021-05-14 | 이장호 | 태아 유래 태초 면역글로불린을 포함하는 세포외소포의 제조방법 |
| WO2022158836A1 (fr) * | 2021-01-21 | 2022-07-28 | 주식회사 엑소코바이오 | Exosome recombinant comprenant un récepteur fc ou une partie de celui-ci auquel une protéine ou un peptide cible est fusible et utilisation associée |
| KR20240007143A (ko) * | 2021-04-14 | 2024-01-16 | 안자리움 바이오사이언시스 아게 | 펩티드, 나노소수포, 및 약물 전달을 위한 이의 용도 |
| KR20230172538A (ko) * | 2021-04-14 | 2023-12-22 | 안자리움 바이오사이언시스 아게 | Fc-유래된 폴리펩티드 |
| GB202107182D0 (en) * | 2021-05-19 | 2021-06-30 | Evox Therapeutics Ltd | Nanoparticle delivery system for production of engineered extracellular vesicles |
| CN113599516B (zh) * | 2021-08-16 | 2022-02-18 | 上海蒙彼利生物技术有限公司 | 制备外泌体方法及其药物组合物在组织修复中的应用 |
| CN117916379A (zh) * | 2021-09-08 | 2024-04-19 | 株式会社梦想实验室 | 用于生物分子的稳定表达及递送的质粒平台 |
| CN113897387B (zh) * | 2021-10-09 | 2023-09-05 | 深圳市汉科生命工程有限公司 | 一种具有促进毛发再生功能的基因重组msc及其外泌体样纳米材料的制备方法和应用 |
| EP4190349A3 (fr) | 2021-12-03 | 2023-08-30 | China Medical University | Production d'exosomes et leurs utilisations |
| CN114107253B (zh) * | 2021-12-17 | 2024-03-15 | 复旦大学附属华山医院 | 一种利用工程细胞进行基因编辑的系统及方法 |
| CN114236113B (zh) * | 2021-12-21 | 2023-07-21 | 南京农业大学 | 一种2,4-滴的即用型免疫传感器 |
| WO2023133425A1 (fr) * | 2022-01-04 | 2023-07-13 | The Broad Institute, Inc. | Compositions et procédés d'administration de cargo à une cellule cible |
| WO2023196586A1 (fr) * | 2022-04-07 | 2023-10-12 | The Regents Of The University Of Michigan | Procédés et dispositifs de criblage de vésicules extracellulaires |
| WO2024064748A2 (fr) * | 2022-09-20 | 2024-03-28 | North Carolina State University | Compositions et procédés associés à l'administration exosomale d'agents thérapeutiques |
| CN116179582A (zh) * | 2022-09-27 | 2023-05-30 | 南京医事达生物科技有限公司 | 一种通用型基因重组蛋白质a亲和纯化填料制备方法和应用 |
| CN117802045A (zh) * | 2022-09-30 | 2024-04-02 | 北京恩康医药有限公司 | 一种工程化细胞外囊泡的构建及其应用 |
| WO2024225847A1 (fr) * | 2023-04-28 | 2024-10-31 | 연세대학교 산학협력단 | Procédé pour isoler des exosomes ou des vésicules extracellulaires issus du cancer du sein |
| CN118725135A (zh) * | 2024-09-02 | 2024-10-01 | 中国科学院苏州纳米技术与纳米仿生研究所 | 外泌体的改造方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999059643A2 (fr) * | 1998-05-20 | 1999-11-25 | Sdg, Inc. | Complexe d'apport par liposomes |
| US20040241176A1 (en) * | 2000-04-27 | 2004-12-02 | Ap Cells. Inc. | Method of producing membrane vesicles |
| US20070128117A1 (en) * | 2003-02-04 | 2007-06-07 | Bracco International B.V. | Ultrasound contrast agents and process for the preparation thereof |
| JP2007295929A (ja) * | 2006-04-05 | 2007-11-15 | Geno Membrane:Kk | イヌＢｓｅｐ遺伝子 |
| EP2198033A4 (fr) * | 2007-08-30 | 2011-05-25 | Virexx Medical Corp | Compositions antigéniques et leur utilisation dans l'administration ciblée d'acides nucléiques |
| JP2010540466A (ja) * | 2007-09-24 | 2010-12-24 | ザ ユニバーシティ オブ クイーンズランド | 分子送達ベシクル |
| US20130053426A1 (en) | 2009-04-17 | 2013-02-28 | Yiqi Seow | Composition For Delivery Of Genetic Material |
| ES2623912T3 (es) * | 2010-12-23 | 2017-07-12 | Janssen Biotech, Inc. | Mutantes FC de anticuerpo activo resistente a proteasa |
| EP2675474B1 (fr) * | 2011-02-15 | 2019-01-16 | Vaxiion Therapeutics, LLC | Compositions thérapeutiques et procédés d'administration ciblée de molécules bioactives par des minicellules bactériennes basée sur des molécules de ciblage contenant un fragment fc et des anticorps |
| GB201121070D0 (en) * | 2011-12-07 | 2012-01-18 | Isis Innovation | composition for delivery of biotherapeutics |
| GB201121069D0 (en) | 2011-12-07 | 2012-01-18 | Isis Innovation | Delivery system |
| US11274139B2 (en) * | 2013-04-12 | 2022-03-15 | Evox Therapeutics Ltd | Therapeutic delivery vesicles |
| WO2015002956A1 (fr) | 2013-07-01 | 2015-01-08 | Ohio State Innovation Foundation | Système de distribution d'exosome |
| US10538570B2 (en) * | 2013-09-30 | 2020-01-21 | Northwestern University | Targeted and modular exosome loading system |
| EP3057662A4 (fr) * | 2013-10-17 | 2017-03-29 | Children's Hospital Los Angeles | Thérapie par exosomes dépendant d'un anticorps |
| WO2015143113A1 (fr) * | 2014-03-20 | 2015-09-24 | Barb Ariel Cohen | Préparations de vésicules extracellulaires dérivées, dosages, et procédés visant à modifier les résultats thérapeutiques de ces préparations |
| GB2552473A (en) * | 2016-07-21 | 2018-01-31 | Evox Therapeutics Ltd | Surface decoration of extracellular vesicles |
-
2016
- 2016-07-21 GB GB1612643.5A patent/GB2552473A/en not_active Withdrawn
-
2017
- 2017-07-21 CA CA3031186A patent/CA3031186A1/fr active Pending
- 2017-07-21 EP EP17749397.0A patent/EP3487529A1/fr not_active Withdrawn
- 2017-07-21 US US16/319,087 patent/US20230181757A1/en not_active Abandoned
- 2017-07-21 CN CN201780045183.0A patent/CN109689098A/zh active Pending
- 2017-07-21 MX MX2019000863A patent/MX2019000863A/es unknown
- 2017-07-21 EP EP23192812.8A patent/EP4299137A3/fr active Pending
- 2017-07-21 CA CA3031183A patent/CA3031183A1/fr active Pending
- 2017-07-21 SG SG11201811151PA patent/SG11201811151PA/en unknown
- 2017-07-21 WO PCT/EP2017/068476 patent/WO2018015535A1/fr unknown
- 2017-07-21 SG SG10202100597TA patent/SG10202100597TA/en unknown
- 2017-07-21 US US16/319,061 patent/US11236143B2/en active Active
- 2017-07-21 CN CN201780045139.XA patent/CN109689097B/zh active Active
- 2017-07-21 KR KR1020197005093A patent/KR20190032479A/ko active Search and Examination
- 2017-07-21 SG SG10202100598RA patent/SG10202100598RA/en unknown
- 2017-07-21 JP JP2019502697A patent/JP7254016B2/ja active Active
- 2017-07-21 SG SG11201811152YA patent/SG11201811152YA/en unknown
- 2017-07-21 BR BR112019001108A patent/BR112019001108A2/pt not_active IP Right Cessation
- 2017-07-21 AU AU2017299214A patent/AU2017299214A1/en not_active Abandoned
- 2017-07-21 BR BR112019001099A patent/BR112019001099A2/pt not_active IP Right Cessation
- 2017-07-21 AU AU2017300035A patent/AU2017300035A1/en not_active Abandoned
- 2017-07-21 MX MX2019000861A patent/MX2019000861A/es unknown
- 2017-07-21 JP JP2019502253A patent/JP7140743B2/ja active Active
- 2017-07-21 KR KR1020197005096A patent/KR102636776B1/ko active IP Right Grant
- 2017-07-21 EP EP17749395.4A patent/EP3487528B1/fr active Active
- 2017-07-21 WO PCT/EP2017/068486 patent/WO2018015539A1/fr unknown
-
2021
- 2021-12-15 US US17/551,582 patent/US20220098267A1/en active Pending
-
2022
- 2022-05-24 JP JP2022084613A patent/JP2022117998A/ja active Pending
- 2022-12-01 JP JP2022192884A patent/JP2023026440A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811151PA (en) | Extracellular vesicle comprising a fusion protein having fc binding capacity | |
| SG11201811150WA (en) | Ev-mediated delivery of binding protein-small molecule conjugates | |
| SG11201810116VA (en) | Exosomes comprising therapeutic polypeptides | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201811184UA (en) | Lag -3 binding members | |
| SG11201809082WA (en) | Nlrp3 modulators | |
| SG11201811148SA (en) | Cell penetrating peptide (cpp)-mediated ev loading | |
| SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
| SG11201811549UA (en) | Boronic acid derivatives and therapeutic uses thereof | |
| SG11201805442XA (en) | Compositions and methods related to multimodal therapeutic cell systems for immune indications | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201805420SA (en) | Antibodies and conjugates thereof | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201811706RA (en) | Process for the preparation of microcapsules | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201807523PA (en) | Ilt7 binding molecules and methods of using the same | |
| SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof |